Prostate cancer metastatic
Not recruitingStudy of ifinatamab deruxtecan alone or in combination with other treatments for patients with metastatic castration-resistant prostate cancer
Study of ifinatamab deruxtecan alone or in combination with other treatments for patients with metastatic castration-resistant prostate cancer
- Disease:Prostate cancer metastatic
- Substances:AbirateroneCodeine Phosphate+8
The Netherlands- Participants:18–64 years · 65+ years
- Substances:Abiraterone
- Sponsor:Merck Sharp & Dohme LLC










